<< Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada | Massive mismanagement leads to catastrophic decline in freshwater biodiversity >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Filipino | हिन्दी | Русский | Svenska | Polski

Investment opportunities in the South African drug delivery devices market

Published on October 13, 2009 at 6:42 AM · No Comments

Research and Markets (http://www.researchandmarkets.com/research/fad8d5/south_africa_drug) has announced the addition of Global Markets Direct's new report "South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2015" to their offering.

South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2015

Summary

This report is an essential source for in-depth information and data relating to South Africa drug delivery devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and the latest news, financial deals and pipeline products information of each of the key sub-segments of the drug delivery devices market in South Africa

Scope

  • The report provides information on the drug delivery devices market in South Africa.
  • Details on the key segments and categories such as Inhalation Systems, Needle Free Injections, and Infusion Systems.
  • Total revenues, products sold, end users, and average pricing.
  • Market shares of all the key competitors such as GlaxoSmithKline plc, AstraZeneca International plc, Novartis AG, Boehringer Ingelheim GmbH, and Fresenius Kabi AG.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading